Evidence map›Paper›PMID 32957746›Full record

Observational studyRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2020

[Description of Influenza B in seasonal epidemic in Cantabria during the beginning of the pandemia due to SARS-CoV-2].

D Pablo-Marcos, A Rodríguez-Fernández, M Gozalo, J Agüero, F Arnaiz de Las Revillas, J Calvo

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

D Pablo-MarcosDaniel Pablo Marcos, Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-IDIVAL. Santander, Spain. daniel.pablo@scsalud.es.
A Rodríguez-Fernández
M Gozalo
J Agüero
F Arnaiz de Las Revillas
J Calvo
Instituto de Investigación Marqués de Valdecilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCo-circulation of the two Influenza B lineages hinders forecast of strain to include in trivalent vaccine. Autonomous Communities such as Cantabria continue without supplying tetravalent vaccine. The aim of this study was to analyse epidemiological characteristics of influenza type B in Cantabria (2019-2020 season) as well as to establish the predominant lineage and its relation to the recommended vaccine.

methodsRetrospective study whereby flu diagnosis and lineage analysis were determined by RT-PCR.

resultsAll samples belonged to the Victoria lineage. Most prevalent viral co-infection was due to SARS-CoV-2. The population affected by influenza B was mainly paediatric and non-vaccinated patients more frequently required hospital admittance.

conclusionsInfluenza type B has a higher incidence in the paediatric population and type A affects more the adult population. Only 28.8% of patients with Influenza B that presented with some underlying condition or risk factor were vaccinated. This shows the need to increase coverage with tetravalent vaccines in order to reduce the burden of disease associated with the Influenza B virus.

Indexed as

Influenza B virusPandemicsSARS-CoV-2AdultChildChi-Square DistributionCoinfectionCOVID-19EpidemicsFemaleHospitalizationHumansInfluenza, HumanInfluenza VaccinesMaleRetrospective StudiesInfluenza VaccinesepidemiologyInfluenzavaccination

Identifiers

PMID32957746
PMCPMC7712335
OpenAlexW3087028320

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.